Reuters logo
Novartis exercises option with Conatus for NASH product
May 4, 2017 / 7:14 AM / 7 months ago

Novartis exercises option with Conatus for NASH product

ZURICH (Reuters) - Novartis is exercising its option with ConatusPharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH, the Swiss drugmaker said.

A sign marks a building on Novartis' campus in Cambridge, Massachusetts, U.S., February 28, 2017. Picture taken February 28, 2017. REUTERS/Brian Snyder

In December, Novartis said it signed a licensing deal to co-develop the fatty liver disease drug with Conatus, under which the small U.S. company receives $50 million up front.

Novartis said on Thursday exercise of the option would take effect upon receipt of all required anti-trust approvals and payment of a $7-million option exercise fee to Conatus. 

Reporting by Michael Shields; Editing by Clarence Fernandez

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below